LAUREN P SILVERNAIL
CIK 1225755 · See Remarks · last filed 2026-06-22
LAUREN P SILVERNAIL is a corporate insider who has filed 71 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for HROW, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$3.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions. 6 SEC filings were submitted jointly with HARROW HEALTH, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.14M
7
71
-$3.28M
Filer Profile
SUITE #100
IRVINE, CA 92618
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HROW | Director | 1,000 | $34.48 | $34.5K | $31.0K | 2 | 2026-06-22 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 0 | $15.50 | $0 | $0 | 3 | 2026-02-10 |
| HARROW, INC. (HROWM) Delisted | Director | — | $26.03 | — | $0 | 3 | 2025-06-24 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 0 | $23.01 | $0 | $0 | 4 | 2024-03-11 |
| EOLS | See Remarks | 141,571 | $7.84 | $1.11M | -$1.03M | 12 | 2022-05-18 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CFO & CBO | 65,497 | $3.65 | $239.1K | -$2.31M | 25 | 2018-05-24 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | Chief Financial Officer | 177,709 | — | — | $21.4K | 21 | 2012-05-10 |
Recent Filings
71 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | HROW | Grant (A) | — | $0 | EDGAR |
| 2026-05-19 | HROW | Buy (P) | +1,000 | $31.0K | EDGAR |
| 2026-02-10 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Disp (D) | −10,075 | $0 | EDGAR |
| 2025-06-24 | HARROW, INC. (HROWM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-13 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | +1,439 | $0 | EDGAR |
| 2025-02-05 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | HARROW, INC. (HROWM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-11 | Harpoon Therapeutics, Inc. (HARP) Delisted | Disp (D) | −5,000 | $0 | EDGAR |
| 2024-01-30 | HARROW, INC. (HROWM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-11-28 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.